Lenalidomide enhances anti-myeloma cellular immunity
Katarina Luptakova(Tesaro (United States)), David Avigan(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Kenneth C. Anderson(Dana-Farber Cancer Institute), Turner Kufe(Beth Israel Deaconess Medical Center), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Brett Glotzbecker(Dana-Farber Cancer Institute), Donald Küfe(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Dina Stroopinsky(Beth Israel Deaconess Medical Center), Heidi Mills(Beth Israel Deaconess Medical Center), D. Tzachanis(Beth Israel Deaconess Medical Center), James D. Levine(Beth Israel Deaconess Medical Center), Jeffrey I. Zwicker(Memorial Sloan Kettering Cancer Center)
Cited by 161
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k